9 citations
,
July 2017 in “Case Reports in Dermatology” Combination therapy helped patient with advanced Hidradenitis Suppurativa achieve remission.
24 citations
,
August 2009 in “Expert opinion on pharmacotherapy” The combination of calcipotriene and betamethasone is more effective and has fewer side effects for treating psoriasis.
2 citations
,
February 2023 in “Research Square (Research Square)” The scaffold effectively prevents melanoma relapse and aids wound healing.
5 citations
,
May 2022 in “Clinical & Experimental Metastasis” Minoxidil and ranolazine together can reduce the spread of certain breast cancer cells.
23 citations
,
December 2013 in “Molecules” N13-substituted evodiamine derivatives improved anticancer activity and solubility, showing promise for drug development.
January 2025 in “International Journal of Pharmaceutics” A new gel improves hair loss treatment by effectively delivering minoxidil and finasteride to the scalp.
10 citations
,
July 2011 in “Archives of Pharmacal Research”
Most patients were satisfied with topical finasteride, and few experienced side effects.
May 2024 in “Biochemical pharmacology” Blocking CISD1 reduces hearing loss from cisplatin in mice.
Metformin shows promise for treating skin conditions, but more research is needed.
March 2005 in “Journal of The American Academy of Dermatology” Diphencyprone treatment protocols could be simplified as no harm occurred despite not fully following them.
January 2005 in “Translational and Clinical Pharmacology” HDMHG0401-10 improves hair loss in men with androgenetic alopecia and has no major side effects.
9 citations
,
March 1991 in “Endocrinology” Using two drugs together, Flutamide and 4-MA, is more effective for blocking male hormones than using each one alone.
July 2025 in “The Journal of Dermatology” 5% topical minoxidil may help reduce hair loss and increase hair growth in telogen effluvium.
12 citations
,
February 1999 in “British Journal of Dermatology” Minoxidil increased small openings in blood vessel walls near growing hair in rats.
February 2018 in “The Journal of Sexual Medicine” DA-9401 protects against hair loss, improves organ function, and prevents infertility caused by finasteride.
29 citations
,
January 1996 in “Journal of Pharmaceutical Sciences” Finasteride poorly inhibits type 1 5AR, affecting its effectiveness.
1 citations
,
April 2004 in “Cancer” Imatinib mesylate can cause skin lightening, especially in Chinese patients, due to its effect on pigment production.
June 2025 in “British Journal of Dermatology” Tofacitinib is more effective than methotrexate for treating moderate-to-severe alopecia areata.
173 citations
,
July 2012 in “British Journal of Dermatology” Dabrafenib can cause skin growths and sometimes low-grade skin cancer.
23 citations
,
October 2012 in “ChemistryOpen” Probe detects finasteride with high selectivity and low detection limit.
2 citations
,
August 2011 in “Cochrane Database of Systematic Reviews”
March 2026 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib improved multiple immune-related conditions in one patient.
September 2024 in “Journal of the American Academy of Dermatology” Generic topical and transdermal systems usually cause minimal irritation or sensitization.
6 citations
,
August 2020 in “Journal of Pharmaceutical Innovation” Nanoemulgel improves hair growth and quality using finasteride without irritation.
7 citations
,
May 2015 in “Journal of The American Academy of Dermatology” Finasteride helps treat frontal fibrosing alopecia, improving or stabilizing the condition in many patients.
April 2024 in “Meždunarodnyj vestnik veterinarii” Deltsid 7.5 is the most effective treatment for bovine psoroptosis.
2 citations
,
September 2023 in “Journal of the American Academy of Dermatology” CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.
January 2026 in “RSC Medicinal Chemistry” 2,5-DBH shows promise for improving drugs in cancer, brain disorders, and infections.
25 citations
,
November 2013 in “Journal of the American Academy of Dermatology” Many patients on new leukemia drugs had mild to moderate skin reactions.